Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeEAM conditioning before autologous stem cell transplantation in relapsed or refractory lymphoma
2008-002736-15Phase 2Completed
- Sponsor
- San Salvatore Hospital of L'Aquila
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, etoposide, cytarabine and melphalan in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Hodgkin lymphoma (HL), sponsored by San Salvatore Hospital of L'Aquila. Primary endpoint: 3-year event-free survival. Started Mar 2009; status: completed.
02
Drugs
bendamustineetoposidecytarabinemelphalan
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2008-002736-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002736-15.